Since its establishment in 1997, Tianlong has been committed to the research and development, production and overall solutions of instruments and in vitro diagnostic reagents in the field of genetic testing and molecular diagnostics. With its own sustainable development and potential values, Tianlong has received investments from SK Group, the 57th largest company in the Fortune Global 500 list, and Kehua Bio-Engineering, a listed company in China, in 2012 and 2018.